Active — Not RecruitingNot Applicable

On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge

United States6 participantsStarted 2024-10-07

Plain-language summary

This study evaluates mucositis and other oral symptoms in patients undergoing photobiomodulation in patients undergoing hematopoietic stem cell transplantation.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * PATIENTS: * Age: ≥ 18 years * Undergoing allogeneic HSCT - cases where PBM was used and cases where PBM was not used NURSES: * Nurses who administer PBM

What they're measuring

Mucositis according to the World Health Organization (WHO) Scale

Timeframe: Up to 22 days or until discharge, whichever came first

Average oral pain

Timeframe: Up to 22 days or until discharge, whichever came first

Taste

Timeframe: Up to 22 days or until discharge, whichever came first

Xerostomia

Timeframe: Up to 22 days or until discharge, whichever came first

Trial details

NCT IDNCT06625619

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-11-24

View on ClinicalTrials.gov More Hematopoietic and Lymphatic System Neoplasm trials